title: Cellular Retinoic Acid Binding Protein 2 Is Strikingly Downregulated in Human Esophageal Squamous Cell Carcinoma and Functions as a Tumor Suppressor.
abstract: Esophageal squamous cell carcinoma (ESCC) is the predominant pathotype of esophageal carcinoma (EC) in China, especially in Henan province, with poor prognosis and limited 5-year survival rate. Cellular retinoic acid binding protein 2 (CRABP2) is a member of the retinoic acid (RA) and lipocalin/cytosolic fatty-acid binding protein family and plays a completely contrary role in tumorigenesis through the retinoid signaling pathway, depending on the nuclear RA receptors (RAR) and PPARbeta/delta receptors. Presently, the biological role of CRABP2 in the development of ESCC has never been reported. Here, we firstly evaluated the expression of CRABP2 at both mRNA and protein levels and showed that it was remarkably downregulated in clinical ESCC tissues and closely correlated with the occurrence position, pathology, TNM stage, size, infiltration depth and cell differentiation of the tumor. Additionally, the biological function assays demonstrated that CRABP2 acted as a tumor suppressor in esophageal squamous carcinogenesis by significantly inhibiting cell growth, inducing cell apoptosis and blocking cell metastasis both in vitro and in vivo. All in all, our finding simplicate that CRABP2 is possibly an efficient molecular marker for diagnosing and predicting the development of ESCC.
authors.affiliation: Department of Clinical Laboratory Medicine, Tenth People's Hospital of Tongji University, Shanghai, 200072, China.
authors.forename: Qingyuan
authors.initials: Q
authors.lastname: Yang
authors.affiliation: Department of Clinical Laboratory Medicine, Tenth People's Hospital of Tongji University, Shanghai, 200072, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
authors.affiliation: Central Laboratory, Tenth People's Hospital of Tongji University, Shanghai, 200072, China.
authors.forename: Weifan
authors.initials: W
authors.lastname: Xiao
authors.affiliation: Department of Clinical Laboratory Medicine, Tenth People's Hospital of Tongji University, Shanghai, 200072, China.
authors.forename: Fenyong
authors.initials: F
authors.lastname: Sun
authors.affiliation: Department of Clinical Laboratory Medicine, The first affiliated hospital of Dalian Medical University, Tianjin, 300070, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Yuan
authors.affiliation: Central Laboratory, Tenth People's Hospital of Tongji University, Shanghai, 200072, China.
authors.forename: Qiuhui
authors.initials: Q
authors.lastname: Pan
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000235:genetics; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D015536:Down-Regulation; D004938:Esophageal Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic; D064593:Heterografts; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D012334:RNA, Neoplasm / Q000096:biosynthesis / Q000235:genetics; D018168:Receptors, Retinoic Acid / Q000096:biosynthesis* / Q000235:genetics; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D018168:Receptors, Retinoic Acid; D025521:Tumor Suppressor Proteins; C082928:retinoic acid binding protein II, cellular
references.citation: Acta Biochim Pol. 2011;58(1):19-29
references.pmid: 21409183
references.citation: Mol Cell Biol. 1999 Oct;19(10):7158-67
references.pmid: 10490651
references.citation: Clin Cancer Res. 2012 Jan 1;18(1):280-9
references.pmid: 22010213
references.citation: Cancer Res. 2012 May 1;72(9):2428-39
references.pmid: 22414580
references.citation: PLoS One. 2012;7(8):e42281
references.pmid: 22876312
references.citation: Int J Cancer. 2012 Oct 15;131(8):1963-8
references.pmid: 22275178
references.citation: PLoS One. 2013;8(1):e55479
references.pmid: 23383201
references.citation: Expert Opin Pharmacother. 2013 Jul;14(10):1345-54
references.pmid: 23675862
references.citation: World J Gastroenterol. 2013 Sep 14;19(34):5598-606
references.pmid: 24039351
references.citation: Hum Pathol. 2014 Jun;45(6):1177-83
references.pmid: 24709110
references.citation: J Chemother. 2014 Aug;26(4):235-42
references.pmid: 24070188
references.citation: Carcinogenesis. 2014 Jul;35(7):1643-51
references.pmid: 24710624
references.citation: Mol Cell Biol. 2014 Jun;34(12):2135-46
references.pmid: 24687854
references.citation: Tumour Biol. 2014 Oct;35(10):10295-300
references.pmid: 25034531
references.citation: J Biol Chem. 2014 Dec 5;289(49):34065-73
references.pmid: 25320093
references.citation: Cancer Res. 2002 Nov 15;62(22):6598-605
references.pmid: 12438255
references.citation: Int J Clin Exp Pathol. 2015;8(9):11224-9
references.pmid: 26617846
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):243-50
references.pmid: 15668501
references.citation: Mol Cell. 2005 Apr 29;18(3):343-53
references.pmid: 15866176
references.citation: Int J Oncol. 2005 Nov;27(5):1273-82
references.pmid: 16211222
references.citation: Int J Oncol. 2006 Dec;29(6):1337-47
references.pmid: 17088971
references.citation: Cell. 2007 May 18;129(4):723-33
references.pmid: 17512406
references.citation: Proc Natl Acad Sci U S A. 2008 May 27;105(21):7546-51
references.pmid: 18495924
references.citation: Neoplasia. 2009 Dec;11(12):1329-39
references.pmid: 20019841
references.citation: Proteomics Clin Appl. 2010 Apr;4(4):449-63
references.pmid: 21137063
references.citation: CA Cancer J Clin. 2015 Mar;65(2):87-108
references.pmid: 25651787
references.citation: Dev Dyn. 2011 May;240(5):1259-70
references.pmid: 21509899